Home › NDC Lookup › RxCUI directory › RxCUI 403972

Fluoxetine 50 MG / olanzapine 6 MG Oral Capsule — RxCUI 403972

RxNorm drug concept · Semantic clinical drug
RxCUI 403972 Semantic clinical drug · SCD ● Current RxNorm concept 15 FDA products 15 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI403972
Official nameFluoxetine 50 MG / olanzapine 6 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asfluoxetine 50 MG (as fluoxetine hydrochloride) / olanzapine 6 MG Oral Capsule; OLANZapine 6 MG / FLUoxetine HCl 50 MG Oral Capsule
FDA products mapped15
Package NDCs mapped15
Reported Medicaid activity (SDUD)5,161 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Olanzapine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Olanzapine helps bring certain brain chemicals — mainly dopamine and serotonin — back into balance. Depending on what it's prescribed for, it can reduce symptoms of psychosis like...
  • What exactly is olanzapine supposed to do for me?
  • Honestly, yes — weight gain and changes in blood sugar and cholesterol are real and well-documented with olanzapine. Some people gain a significant amount of weight. Blood sugar ca...
  • Will olanzapine make me gain weight or affect my blood sugar?
📖 Read our full Olanzapine guide →

🕸️ Concept Web — How Fluoxetine 50 MG / olanzapine 6 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Fluoxetine 50 MG / olanzapine 6 MG Oral Capsule RxCUI 403972

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Fluoxetine 4493
    • Olanzapine 61381
    • Fluoxetine / olanzapine 611247
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fluoxetine / olanzapine Oral Capsule 406024
    • Fluoxetine / olanzapine Oral Product 1160833
    • Fluoxetine / olanzapine Pill 1160834
    • Oral Capsule 316965
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 2

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Fluoxetine 50 MG 406026
    • Olanzapine 6 MG 406025

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Fluoxetine 50 MG SCDC · 406026
  • Olanzapine 6 MG SCDC · 406025
  • Fluoxetine / olanzapine Oral Capsule SCDF · 406024
  • Fluoxetine / olanzapine Oral Product SCDG · 1160833
  • Fluoxetine / olanzapine Pill SCDG · 1160834

📦 FDA Products & Package NDCs

15 products · 15 package NDCs
15 package NDCs map to RxCUI 403972 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00093-5503-56 30 CAPSULE in 1 BOTTLE (0093-5503-56) Olanzapine and Fluoxetine Teva Pharmaceuticals USA, Inc. 2013-04-10
00093-5504-56 30 CAPSULE in 1 BOTTLE (0093-5504-56) Olanzapine and Fluoxetine Teva Pharmaceuticals USA, Inc. 2012-06-19
00093-5505-56 30 CAPSULE in 1 BOTTLE (0093-5505-56) Olanzapine and Fluoxetine Teva Pharmaceuticals USA, Inc. 2012-06-19
00093-5506-56 30 CAPSULE in 1 BOTTLE (0093-5506-56) Olanzapine and Fluoxetine Teva Pharmaceuticals USA, Inc. 2012-06-19
00093-5507-56 30 CAPSULE in 1 BOTTLE (0093-5507-56) Olanzapine and Fluoxetine Teva Pharmaceuticals USA, Inc. 2012-06-19
42291-0652-30 30 CAPSULE in 1 BOTTLE (42291-652-30) Olanzapine and Fluoxetine AvKARE 2014-01-21
42291-0653-30 30 CAPSULE in 1 BOTTLE (42291-653-30) Olanzapine and Fluoxetine AvKARE 2014-01-21
42291-0654-30 30 CAPSULE in 1 BOTTLE (42291-654-30) Olanzapine and Fluoxetine AvKARE 2014-01-21
42291-0655-30 30 CAPSULE in 1 BOTTLE (42291-655-30) Olanzapine and Fluoxetine AvKARE 2014-01-21
42291-0656-30 30 CAPSULE in 1 BOTTLE (42291-656-30) Olanzapine and Fluoxetine AvKARE 2014-01-21
49884-0250-11 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-250-11) Olanzapine and Fluoxetine Par Health USA, LLC 2012-11-26
49884-0251-11 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-251-11) Olanzapine and Fluoxetine Par Health USA, LLC 2012-11-26
49884-0252-11 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-252-11) Olanzapine and Fluoxetine Par Health USA, LLC 2012-11-26
49884-0253-11 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-253-11) Olanzapine and Fluoxetine Par Health USA, LLC 2012-11-26
49884-0277-11 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-277-11) Olanzapine and Fluoxetine Par Health USA, LLC 2012-11-26
Observed labelers: AvKARE (5) · Par Health USA, LLC (5) · Teva Pharmaceuticals USA, Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.